Experimental vaccine trains immune system to fight multiple cancers

NCT ID NCT01147965

Completed Disease control Sponsor: NantCell, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a cancer vaccine called ETBX-011 in 43 people with advanced colorectal, lung, breast, or prostate cancers that produce a protein called CEA. The vaccine uses a modified virus to teach the immune system to attack cancer cells making CEA. The main goals were to check safety and see if the vaccine triggers an immune response against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ad5 [E1-, E2b-]-CEA(6D) vector vaccine (ETBX-011)
What this could lead to: If successful, this vaccine could help the immune system recognize and attack cancer cells that produce CEA, potentially slowing tumor growth or shrinking tumors in advanced cancers.
What could go wrong: This is an early-phase trial with only 43 participants, so the vaccine may not prove effective or safe in larger groups. It is designed for advanced cancers, so benefits may be limited and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colonic neoplasm colorectal cancer colorectal neoplasm lung cancer lung neoplasm malignant pancreatic neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLORECTAL CANCER LUNG CANCER PROSTATE CANCER

Contacts and locations

Locations

Duke Cancer Research Institute, Duke University

Durham, North Carolina, 27710, United States
Medical Oncology Associates, PS

Spokane, Washington, 99208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.